LabGenius announces research collaboration with Ablynx

By The Science Advisory Board staff writers

July 16, 2021 -- LabGenius has announced a research collaboration with Ablynx, a Sanofi company, for therapeutic proteins.

The company develops machine learning for protein engineering via its machine learning-driven evolution engine (EVA platform) and will combine its expertise with Ablynx's existing therapeutic Nanobody protein technology, it said. The optimized candidates will then be advanced by Ablynx into further validation studies.

Financial terms of the partnership were not disclosed.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
BrickBio advances conjugation platform for therapeutic development
BrickBio has demonstrated the power of its conjugation platform process for the commercial development of biologics in-house and with pharmaceutical partners.

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter